التفاصيل البيبلوغرافية
| العنوان: |
Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats. |
| المؤلفون: |
Ke-ke Qi, Jia-jia Lv, Jie Wu, Zi-wei Xu, Qi, Ke-Ke, Lv, Jia-Jia, Wu, Jie, Xu, Zi-Wei |
| المصدر: |
BMC Gastroenterology; 3/4/2017, Vol. 17, p1-8, 8p, 3 Charts, 2 Graphs |
| مصطلحات موضوعية: |
POLYETHYLENE glycol, GLUCAGON-like peptides, COLITIS treatment, ULCERATIVE colitis, LABORATORY rats, DEXTRAN sulfate, SODIUM sulfate, ANIMAL experimentation, BIOLOGICAL models, BODY weight, COLON (Anatomy), CYTOKINES, DEXTRAN, DOSE-effect relationship in pharmacology, DUODENUM, INTESTINAL mucosa, MEMBRANE proteins, RATS |
| مستخلص: |
Background: Polyethylene glycosylated (PEGylated) porcine glucagon-like peptide-2 (pGLP-2) considerably increases half-life and stability compared with the native pGLP-2, but the effective dose for intestinal damage is still unclear. This study aims to evaluate the available dose of polyethylene glycosylated porcine glucagon-like peptide-2 (PEG-pGLP-2), a modified, long-acting form of pGLP-2 in an experimental rat model of ulcerative colitis.Methods: Thirty-five male rats were randomly assigned into five groups: control, dextran sodium sulphate (DSS), DSS + PEG-pGLP-2(L), DSS + PEG-pGLP-2(M) and DSS + PEG-pGLP-2(H). Rats in control group received only water; other rats were fed with 5% (w/v) DSS and intraperitoneally administered with 12.5, 25 and 100 nmol/kg PEG-pGLP-2 daily for 6 days.Results: Compared with the control treatment, DSS treatment significantly (p < 0.05) decreased body weight change, colonic length, duodenal villus height and expression of zonula occludens-1, whereas significantly (p < 0.05) increased colonic damage score and expression of claudin-1, interleukin (IL)-1, IL-7, IL-10, interferon-γ and tumour necrosis factor (TNF)-α in colon. However, the three doses of PEG-pGLP-2 all reduced these effects; these treatments significantly (p < 0.05) increased body weight change and duodenal villus height, whereas significantly (p < 0.05) decreased colonic damage score and expression of IL-1, IL-7 and TNF-α in colon. Specifically, low-dose (12.5 nmol/kg/d) PEG-pGLP-2 was effective.Conclusions: These results indicated that PEG-pGLP-2 is a novel and potentially effective therapy for intestinal healing in a relatively low dose. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Gastroenterology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder